Bart Remmerie

2.2k total citations
46 papers, 1.7k citations indexed

About

Bart Remmerie is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Neurology. According to data from OpenAlex, Bart Remmerie has authored 46 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Psychiatry and Mental health, 19 papers in Pediatrics, Perinatology and Child Health and 5 papers in Neurology. Recurrent topics in Bart Remmerie's work include Schizophrenia research and treatment (28 papers), Pharmaceutical studies and practices (13 papers) and Bipolar Disorder and Treatment (10 papers). Bart Remmerie is often cited by papers focused on Schizophrenia research and treatment (28 papers), Pharmaceutical studies and practices (13 papers) and Bipolar Disorder and Treatment (10 papers). Bart Remmerie collaborates with scholars based in United States, Belgium and Netherlands. Bart Remmerie's co-authors include Mariëlle Eerdekens, David Hough, Srihari Gopal, Erik Mannaert, Cristiana Gassmann-Mayer, Rosanne Lane, Joris Berwaerts, Isaac Nuamah, Marc De Meulder and Ilse Van Hove and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Biological Psychiatry.

In The Last Decade

Bart Remmerie

44 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bart Remmerie United States	22	1.2k	330	255	219	201	46	1.7k
Jonathan M. Meyer United States	28	2.6k 2.2×	191 0.6×	310 1.2×	299 1.4×	366 1.8×	95	3.7k
Stephen R. Saklad United States	19	860 0.7×	242 0.7×	241 0.9×	96 0.4×	153 0.8×	45	1.5k
Srihari Gopal United States	29	2.4k 2.0×	480 1.5×	359 1.4×	595 2.7×	534 2.7×	91	2.9k
Georgios Schoretsanitis Switzerland	25	1.4k 1.1×	398 1.2×	504 2.0×	120 0.5×	230 1.1×	169	2.2k
Y. W. Francis Lam United States	21	555 0.5×	300 0.9×	332 1.3×	43 0.2×	100 0.5×	74	1.7k
D. A. W. Johnson United States	25	1.1k 1.0×	109 0.3×	368 1.4×	283 1.3×	389 1.9×	46	1.8k
Silvia Alessi‐Severini Canada	22	492 0.4×	162 0.5×	113 0.4×	65 0.3×	164 0.8×	69	1.3k
Thomas Shiovitz United States	16	554 0.5×	96 0.3×	303 1.2×	30 0.1×	179 0.9×	28	1.2k
Judith C. Kando United States	15	741 0.6×	199 0.6×	264 1.0×	61 0.3×	135 0.7×	40	1.2k
Neil B. Sandson United States	14	689 0.6×	139 0.4×	109 0.4×	167 0.8×	248 1.2×	27	1.1k

Countries citing papers authored by Bart Remmerie

Since Specialization

Citations

This map shows the geographic impact of Bart Remmerie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bart Remmerie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bart Remmerie more than expected).

Fields of papers citing papers by Bart Remmerie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bart Remmerie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bart Remmerie. The network helps show where Bart Remmerie may publish in the future.

Co-authorship network of co-authors of Bart Remmerie

This figure shows the co-authorship network connecting the top 25 collaborators of Bart Remmerie. A scholar is included among the top collaborators of Bart Remmerie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bart Remmerie. Bart Remmerie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lee, Chien‐Chang, et al.. (2025). Closing the gaps in the access to quality-assured medicines for global health: The case for oxytocin for postpartum haemorrhage. Expert Review of Clinical Pharmacology. 18(1-2). 41–49.

Salvadore, Giacomo, Pascal Bonaventure, Anantha Shekhar, et al.. (2020). Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans. Translational Psychiatry. 10(1). 308–308. 31 indexed citations

Remmerie, Bart, et al.. (2019). A Receiver Operating Characteristic Framework for Non-adherence Detection Using Drug Concentration Thresholds—Application to Simulated Risperidone Data in Schizophrenic Patients. The AAPS Journal. 21(3). 40–40. 2 indexed citations

Remmerie, Bart, Thomas Van Looy, Sarah Rusch, et al.. (2019). Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor. Advances in Therapy. 37(1). 578–591. 2 indexed citations

Green, Bruce, et al.. (2018). Determination of plasma concentration reference ranges for oral aripiprazole, olanzapine, and quetiapine. European Journal of Clinical Pharmacology. 74(5). 593–599. 11 indexed citations

Melkote, Rama, Arun Singh, An Vermeulen, Bart Remmerie, & Adam Savitz. (2018). Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. Schizophrenia Research. 201. 324–328. 7 indexed citations

Cleton, Adriaan, Stefaan Rossenu, Herta Crauwels, et al.. (2014). A single‐dose, open‐label, parallel, randomized, dose‐proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. The Journal of Clinical Pharmacology. 54(9). 1048–1057. 39 indexed citations

Rossenu, Stefaan, Adriaan Cleton, David Hough, et al.. (2014). Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Clinical Pharmacology in Drug Development. 4(4). 270–278. 22 indexed citations

Fleischhacker, W. Wolfgang, Srihari Gopal, Rosanne Lane, et al.. (2011). A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. The International Journal of Neuropsychopharmacology. 15(1). 107–118. 101 indexed citations

10.

Gopal, Srihari, David Hough, Haiyan Xu, et al.. (2010). Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. International Clinical Psychopharmacology. 25(5). 247–256. 133 indexed citations

11.

Berwaerts, Joris, Rosanne Lane, Isaac Nuamah, et al.. (2010). Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: A randomized, placebo-controlled study. Journal of Affective Disorders. 129(1-3). 252–260. 49 indexed citations

12.

Meulder, Marc De, Bart Remmerie, Ronald P. de Vries, et al.. (2008). Validated LC–MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine. Journal of Chromatography B. 870(1). 8–16. 56 indexed citations

13.

Vermeir, Marc, Bart Remmerie, Geert Mannens, et al.. (2008). Absorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans. Drug Metabolism and Disposition. 36(4). 769–779. 133 indexed citations

14.

Aman, Michael G., Alexander A. Vinks, Bart Remmerie, et al.. (2007). Plasma Pharmacokinetic Characteristics of Risperidone and Their Relationship to Saliva Concentrations in Children with Psychiatric or Neurodevelopmental Disorders. Clinical Therapeutics. 29(7). 1476–1486. 35 indexed citations

15.

Гефверт, О., Bo Eriksson, Per Persson, et al.. (2005). Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta™) in patients with schizophrenia. The International Journal of Neuropsychopharmacology. 8(1). 27–36. 88 indexed citations

16.

Mannaert, Erik, An Vermeulen, Bart Remmerie, Philippe Bouhours, & J. C. Levron. (2005). Pharmacokinetic profile of long-acting injectable risperidone at steady-state : comparison with oral administration. L Encéphale. 31(5). 609–615. 26 indexed citations

17.

Eerdekens, Mariëlle, Ilse Van Hove, Bart Remmerie, & Erik Mannaert. (2004). Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophrenia Research. 70(1). 91–100. 133 indexed citations

18.

Schaick, E.A. van, Philippe Lechat, Bart Remmerie, et al.. (2003). Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clinical Therapeutics. 25(6). 1687–1699. 37 indexed citations

19.

Remmerie, Bart, et al.. (2002). Validated method for the determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography–tandem mass spectrometry. Journal of Chromatography B. 783(2). 461–472. 78 indexed citations

20.

Ahonen, Jouni, Klaus T. Olkkola, Markku Hynynen, et al.. (2000). Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery†. British Journal of Anaesthesia. 85(4). 533–540. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact